CD19 and Decreased circulating immunoglobulin concentration: Given mixed data on the impact of hypogammaglobulinemia on infectious risk after CD19-directed CAR T-cell therapy, as well as the preservation of pathogen-specific antibodies detected after CD19-directed therapy, we would suggest a tailored approach to IgRT in this subset of CAR-T recipients.